Sino Biopharmaceutical Limited (SBMFF)

Sino Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	11,104	9,570	9,452	12,066	10,569	11,259
Short-Term Investments	-	220.64	1,553	-	569.5	956.01
Trading Asset Securities	8,719	5,028	3,113	4,855	4,656	4,217
Cash & Short-Term Investments	19,823	14,818	14,118	16,922	15,794	16,432
Cash Growth	50.41%	4.96%	-16.57%	7.14%	-3.88%	-13.99%
Accounts Receivable	8,154	5,013	4,596	4,643	4,285	2,914
Other Receivables	291.86	1,787	1,602	1,575	1,164	1,162
Receivables	8,446	6,800	6,199	6,219	5,537	4,076
Inventory	2,104	2,373	1,993	2,329	1,938	1,880
Prepaid Expenses	3,447	694.17	582.57	465.69	234.13	406.58
Other Current Assets	-	-	912.71	-	-	-
Total Current Assets	33,820	24,685	23,806	25,935	23,503	22,794
Property, Plant & Equipment	10,054	10,288	9,912	9,251	8,516	8,392
Long-Term Investments	26,927	26,337	25,181	25,230	25,169	13,857
Goodwill	911.71	915.69	680.45	662.61	647.93	88.93
Other Intangible Assets	2,208	271.89	248.49	278.35	291.56	225.35
Long-Term Deferred Tax Assets	483.7	516.29	567.01	505.15	334.87	463.37
Long-Term Deferred Charges	-	1,873	1,980	973.49	772.46	699.36
Other Long-Term Assets	489.79	520.8	1,230	1,229	1,308	690.21
Total Assets	74,894	65,408	63,605	64,064	60,543	47,210
Accounts Payable	2,820	1,497	1,335	1,884	1,795	1,948
Accrued Expenses	-	7,651	6,716	6,299	5,146	4,190
Short-Term Debt	-	-	136.13	136.13	136.13	-
Current Portion of Long-Term Debt	8,852	7,602	11,136	9,663	6,521	1,553
Current Portion of Leases	20.26	28.33	71.49	60.43	64.47	28.7
Current Income Taxes Payable	383.89	318.2	271.87	107.46	101.17	60.7
Current Unearned Revenue	-	253.24	282.6	310.79	238.2	202.22
Other Current Liabilities	12,774	2,206	2,658	1,690	1,344	2,961
Total Current Liabilities	24,851	19,556	22,607	20,151	15,345	10,944
Long-Term Debt	2,999	1,997	1,074	3,934	5,213	12,363
Long-Term Leases	84.02	83.39	298.39	324.26	319.95	264.86
Long-Term Unearned Revenue	628.94	557.92	548.27	749.07	674.45	608.2
Long-Term Deferred Tax Liabilities	357.73	237.55	781.54	831.79	881.59	171.65
Other Long-Term Liabilities	195.95	201.9	125.46	131.08	380.78	439.19
Total Liabilities	29,117	22,634	25,435	26,121	22,814	24,791
Common Stock	413.68	414.38	414.62	414.9	415.44	415.9
Additional Paid-In Capital	-	12,421	12,443	12,484	12,578	12,691
Retained Earnings	-	25,281	23,649	28,358	27,215	13,603
Treasury Stock	-2,997	-2,975	-1,770	-1,432	-689.35	-469.94
Comprehensive Income & Other	35,957	-3,180	-4,262	-10,078	-9,228	-9,493
Total Common Equity	33,374	31,961	30,474	29,747	30,291	16,747
Minority Interest	12,404	10,813	7,695	8,197	7,438	5,672
Shareholders' Equity	45,778	42,774	38,170	37,944	37,729	22,420
Total Liabilities & Equity	74,894	65,408	63,605	64,064	60,543	47,210
Total Debt	11,956	9,711	12,716	14,118	12,254	14,210
Net Cash (Debt)	7,867	5,107	1,402	2,804	3,540	2,222
Net Cash Growth	124.61%	264.34%	-50.00%	-20.81%	59.33%	-78.82%
Net Cash Per Share	0.43	0.28	0.08	0.15	0.18	0.12
Filing Date Shares Outstanding	18,004	17,924	18,347	18,468	18,699	18,781
Total Common Shares Outstanding	18,004	17,924	18,347	18,468	18,699	18,781
Working Capital	8,970	5,129	1,199	5,784	8,158	11,851
Book Value Per Share	1.85	1.78	1.66	1.61	1.62	0.89
Tangible Book Value	30,254	30,773	29,546	28,806	29,352	16,433
Tangible Book Value Per Share	1.68	1.72	1.61	1.56	1.57	0.87
Buildings	-	5,016	4,248	3,871	3,571	3,656
Machinery	-	8,433	7,628	6,692	6,132	5,546
Construction In Progress	-	1,701	1,686	1,804	1,426	987.83
Leasehold Improvements	-	-	-	-	-	0.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.